Therapeutic methods for muscular or neuromuscular disorders

Details Therapeutic methods for muscular or neuromuscular disorders Therapeutic methods for muscular or neuromuscular disorders

2004-06-01

2010-08-31

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C514S001000, C514S002600, C530S350000

Reexamination Certificate

active

07785587

ABSTRACT:
The disclosure provides methods for treating neuromuscular disorders in mammals. The disclosed methods include administering therapeutically effective amounts of a GDF-8 inhibitor and a corticosteroid to a subject susceptible to, or having, a neuromuscular disorder, so as to maintain desirable levels of muscle function.

REFERENCES:
patent: 4370976 (1983-02-01), Wanchik et al.
patent: 5130141 (1992-07-01), Law et al.
patent: 5562717 (1996-10-01), Tippey et al.
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5756457 (1998-05-01), Wang et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6340668 (2002-01-01), Celeste et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6372454 (2002-04-01), Duan et al.
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6465239 (2002-10-01), Lee et al.
patent: 6607884 (2003-08-01), Lee et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7192717 (2007-03-01), Hill et al.
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7320789 (2008-01-01), Aghajanian et al.
patent: 7381528 (2008-06-01), Lee et al.
patent: 7393682 (2008-07-01), Lee et al.
patent: 2002/0127234 (2002-09-01), El Halawani et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2002/0157125 (2002-10-01), Lee et al.
patent: 2003/0074680 (2003-04-01), Lee et al.
patent: 2003/0104406 (2003-06-01), Wolfman et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2003/0162714 (2003-08-01), Hill et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0055027 (2004-03-01), Lee et al.
patent: 2004/0077053 (2004-04-01), Lee et al.
patent: 2004/0138118 (2004-07-01), Wolfman et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0014733 (2005-01-01), Whittemore
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0240487 (2006-10-01), Nowak et al.
patent: 2006/0240488 (2006-10-01), Nowak et al.
patent: 2008/0178310 (2008-07-01), Lee et al.
patent: 2008/0213426 (2008-09-01), Lee et al.
patent: 1 061 940 (2003-12-01), None
patent: 1 444 985 (2004-08-01), None
patent: WO 94/21681 (1994-09-01), None
patent: WO 94-26892 (1994-11-01), None
patent: WO 96-01845 (1996-01-01), None
patent: WO 98/33887 (1998-08-01), None
patent: WO98/35019 (1998-08-01), None
patent: WO 99/02667 (1999-01-01), None
patent: WO 99/06559 (1999-02-01), None
patent: WO 99/24058 (1999-05-01), None
patent: WO 99/24618 (1999-05-01), None
patent: WO 99/40181 (1999-08-01), None
patent: WO 99/45949 (1999-09-01), None
patent: WO 99/56768 (1999-11-01), None
patent: WO 00/11163 (2000-03-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 01/05820 (2001-01-01), None
patent: WO 01-64888 (2001-09-01), None
patent: WO 02/09641 (2002-02-01), None
patent: WO 02/29105 (2002-04-01), None
patent: WO 02/068650 (2002-09-01), None
patent: WO 03/027248 (2003-04-01), None
patent: WO 03/037248 (2003-05-01), None
patent: WO 03/072714 (2003-09-01), None
patent: WO 03/072715 (2003-09-01), None
patent: WO 2004/024092 (2004-03-01), None
patent: WO 2004/037861 (2004-05-01), None
patent: WO2004/037861 (2004-05-01), None
patent: WO 2004/039948 (2004-05-01), None
patent: WO2004/039948 (2004-05-01), None
patent: WO2004-058988 (2004-07-01), None
patent: WO 2004/108157 (2004-12-01), None
patent: WO 2006/020884 (2006-02-01), None
patent: WO 2006/102574 (2006-09-01), None
patent: WO 2006/107611 (2006-10-01), None
Solomon and Bouloux, J. Endocr. 191: 349-360, 2006.
McKenzie et al., Eur. J. Biochem. 269: 2010-2015, 2002.
Reitter B., Brain and Dev.17: 39-43, 1995.
Richard Robinson, Biology, vol. 3, pp. 108-109, 2002.
Haidet et al., PNAS 105: 4318-4322, 2008.
International Search Report, mailed Dec. 6, 2004 for International Patent Application No. PCT/US04/017049.
Granchelli et al., “Pre-Clinical Screening of Drugs Using themdxMouse,”Neuromuscular Disorders10:235-239 (2000).
Hudecki et al., “Strength and Endurance In the Therapeutic Evaluation of Prednisolone-Treated MDX Mice,”Res. Comm. Chem. Path. Pharma.79:45-60 (1993).
Lang et al., “Regulation of Myostatin by Glucocorticoids After Thermal Injury,”FASEB J.15:1807-1809 (2001).
Merlini et al., “Early Prednisone Treatment in Duchenne Muscular Dystrophy,”Muscle&Nerve27:222-227 (2003).
Muntoni et al., “Steroids in Duchenne Muscular Dystrophy: From Clinical Trials to Genomic Research,”Neuromuscular Disorders12:S162-S165 (2002).
Alexander et al., “Human Parathyroid Hormone 1-34 Reverses Bone Loss In Ovariectomized Mice,”J. Bone Miner. Res.16:1665-1673 (2001).
Alliel et al., “Testican, a Multidomain Testicular Proteoglycan Resembling Modulators of Cell Social Behaviour,”Eur. J. Biochem.214:347-350 (1993).
Amthor et al., “The Expression and Regulation of Follistatin and a Follistatin-like Gene During Avian Somite Compartmentalization and Myogenesis,”Dev. Biol.178:343-362 (1996).
Andersson et al., “Repeated In Vivo Determinations of Bone Mineral Density During Parathyroid Hormone Treatment in Ovariectomized Mice,”J. Endocrinol.170:529-537 (2001).
Attisano et al., “Activation of Signalling by the Activin Receptor Complex,”Mol. Cell. Biol.16:1066-1073 (1996).
Bartholin et al., “FLRG, an Activin-Binding Protein, is a New Target of TGFβ Transcription Activation Through Smad Proteins,”Oncogene20:5409-5419 (2001).
Brown et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3,”Growth Factors3:35-43 (1990).
D'Angelo et al., “Authentic Matrix Vesicles Contain Active Metalloproteases (MMP),”J. Biol. Chem.276:11347-11353 (2001).
Derynck et al., “Human Transforming Growth Factor-β Complementary DNA Sequence and Expression in Normal and Transformed Cells,”Nature316:701-705 (1985).
Donoghue et al., “Rostrocaudal Gradient of Transgene Expression in Adult Skeletal Muscle,”Proc. Natl. Acad. Sci. U.S.A.88:5847-5851 (1991).
Gamer et al., “Gdf11 is a Negative Regulator of Chondrogenesis and Myogenesis in the Developing Chick Limb,”Dev. Biol.229:407-420 (2001).
Gentry et al., “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor,”Biochemistry29:6851-6857 (1990).
Hayette et al., “FLRG (Follistatin-Related Gene), A New Target of Chromosomal Rearrangement in Malignant Blood Disorders,”Oncogene16:2949-2954 (1998).
Hoodless et al., “Mechanisms and Function of Signaling by the TGFβ Superfamily,”Curr. Top. Microbiol. Immunol.228:236-272 (1998).
Huet et al., “Skeletal Muscle Cell Hypertrophy Induced by Inhibitors of Metalloproteases; Myostatin as a Potential Mediator,”Am. J. Physiol. Cell. Physiol.281:C1624-C1634 (2001).
Jiang et al., “Characterization and Identification of the Inhibitory Domain of GDF-8 Propeptide,”Biochem. Biophys. Res. Commun.315:525-531 (2004).
Kato, “A Secreted Tumor-Suppressor, mac25, with Activin-Binding Activity,”Mol. Med.6:126-135 (2000).
Kessler et al., “Bone Morphogenetic Protein-1: The Type I Procollagen C-Proteinase,”Science271:360-362 (1996).
Kingsley, D.M., “The TGF-β Superfamily: New Members, New Receptors, and New Genetic Tests of Function in Different Organisms,”Genes Dev.8:133-146 (1994).
Lee et al., “Analysis of Site-Directed Mutations

Affiliated with

Also associated with

Rating

Therapeutic methods for muscular or neuromuscular disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic methods for muscular or neuromuscular disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods for muscular or neuromuscular disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4149910